GANX (Gain Therapeutics) Total Equity: $14.01 Mil (As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.75
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Total Equity?

Gain Therapeutics GANX +1.74% 31 Total Equity is $14.01 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Gain Therapeutics's total equity for the quarter that ended in Mar. 2026 was $14.01 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Gain Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Total Equity Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 34.82 18.88 12.58 7.34 18.57

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.78 3.70 5.91 18.57 14.01
GANX
31GF Score
Gain Therapeutics Inc GANX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Gain Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=22.819-4.254
=18.57

Gain Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=18.738-4.731
=14.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $14.01 Mil mean?
Gain Therapeutics (GANX) has a Total Equity of $14.01 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Gain Therapeutics and its competitors.
Is Gain Therapeutics' Total Equity too high?
Gain Therapeutics' current Total Equity is $14.01 Mil. Overall, Gain Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Total Equity compare to HYFT and ELTX?
Gain Therapeutics' Total Equity of $14.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Gain Therapeutics and its competitors. Gain Therapeutics's current Total Equity is $14.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Total Equity of $14.01 Mil. The current Total Equity is $14.01 Mil. Gain Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Total Equity is $14.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price